A multi-university consortium running breed-stratified dose-finding work for an investigational mTOR-modulating compound has confirmed that Boxers, Bernese Mountain Dogs, and Cavalier King Charles Spaniels will join the existing cohort of Labradors, Golden Retrievers, German Shepherds, and mixed-breed dogs. The expansion was announced quietly through a clinical trial registry update rather than a press release, which is itself meaningful — researchers in this space are increasingly cautious about overpromising.
The three additions matter because each represents a known gap in canine pharmacokinetic data. Boxers carry a mast cell tumour predisposition that interacts with several immunosuppressive pathways. Bernese Mountain Dogs have one of the highest documented rates of histiocytic sarcoma and one of the shortest median lifespans among large breeds, making them simultaneously the highest-need and highest-risk cohort for a longevity intervention. Cavaliers carry well-documented mitral valve disease patterns that overlap mechanistically with several geroscience targets.
The study's primary endpoint remains pharmacokinetic — measuring how each breed metabolizes the compound across a range of doses, with safety markers as the secondary endpoint. The team is explicitly not powered to detect lifespan differences in this phase. What they are powered to detect is whether the standard dose derived from the original Labrador-and-mixed-breed cohort is also safe, sub-therapeutic, or supra-therapeutic in the three new breeds.
Owners interested in enrollment should know that recruitment is being handled through partner veterinary teaching hospitals rather than a central call line. Eligibility criteria include age (typically 7-11 years depending on breed), absence of active malignancy, and a willingness to commit to 18 months of monthly check-ins. Travel is reimbursed within the consortium's regional footprint.
The expansion is a useful signal for the broader field. Breed-specific dose data has been the single most-requested deliverable from veterinary practitioners surveyed about longevity drugs over the last two years. Once this study reads out, the major commercial programmes will be under pressure to either match it or explain why they didn't.